Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.09 - $6.86 $102,250 - $171,500
25,000 Added 102.46%
49,399 $312,000
Q3 2022

Nov 14, 2022

BUY
$5.41 - $6.74 $131,998 - $164,449
24,399 New
24,399 $125,000

Others Institutions Holding FSTX

About F-star Therapeutics, Inc.


  • Ticker FSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,584,700
  • Description
  • F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...
More about FSTX
Track Prem Watsa's Portfolio

Track Prem Watsa Portfolio

Follow Prem Watsa (Fairfax Financial Holdings LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfax Financial Holdings LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fairfax Financial Holdings LTD and Prem Watsa with notifications on news.